Wee1 inhibitors and methods for treating cancer
Novel WEE1 inhibitors and degraders, represented by compounds of Formula (I), address the inadequacies of existing treatments by targeting cancer cells to induce mitotic catastrophe and enhance tumor sensitivity to DNA-damaging agents, offering a broad spectrum of cancer treatment options.
WO2026128433A1PCT designated stage Publication Date: 2026-06-18RECURIUM IP HLDG LLC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- RECURIUM IP HLDG LLC
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
Smart Images
Figure US2025058721_18062026_PF_FP_ABST
Abstract
Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
Need to check novelty before this filing date? Find Prior Art